Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial

BACKGROUND: Bisphosphonates are the standard of care for reducing the risk of skeletal-related events in patients with bone lesions from multiple myeloma. The MRC Myeloma IX study was designed to compare the effects of zoledronic acid versus clodronic acid in newly diagnosed patients with multiple m...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgan, Gareth J, Child, J Anthony, Gregory, Walter M, Szubert, Alex J, Cocks, Kim, Bell, Sue E, Navarro-Coy, Nuria, Drayson, Mark T, Owen, Roger G, Feyler, Sylvia, Ashcroft, A John, Ross, Fiona M, Byrne, Jennifer, Roddie, Huw, Rudin, Claudius, Cook, Gordon, Jackson, Graham H, Wu, Ping, Davies, Faith E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2011
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3148431/
https://www.ncbi.nlm.nih.gov/pubmed/21771568
http://dx.doi.org/10.1016/S1470-2045(11)70157-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3148431/
https://www.ncbi.nlm.nih.gov/pubmed/21771568
http://dx.doi.org/10.1016/S1470-2045(11)70157-7

Ejemplares similares